GO:0005008 hepatocyte growth factor receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005008 (hepatocyte growth factor receptor activity) is a molecular function defined as combining with hepatocyte growth factor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.
• The receptor is the MET tyrosine kinase, which binds HGF and activates downstream signaling including phosphatidylinositol 3-kinase.
• HGF/MET signaling drives hepatocyte proliferation and liver regeneration, as shown in partial hepatectomy models.
• MET activation is tightly controlled by ligand binding and receptor ubiquitination, and activating ubiquitin multimers can stimulate MET.
• Dysregulated HGF/MET signaling is implicated in cancer, neuroinflammation, and cardiovascular protection.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of MET signaling in disease.
Description
Hepatocyte growth factor receptor activity (GO:0005008) is a molecular function that mediates the cellular response to hepatocyte growth factor (HGF). The receptor, encoded by the MET gene, is a receptor tyrosine kinase that binds HGF and transmits signals across the plasma membrane to initiate changes in cell activity. This activity is central to embryogenesis, tissue regeneration, and cancer progression, making it a major focus of biomedical research. The HGF/MET axis is one of the most studied receptor-ligand systems in oncology and regenerative medicine, and its dysregulation is linked to tumorigenesis, metastasis, and impaired tissue repair. Understanding the precise molecular mechanism of GO:0005008 is therefore essential for developing targeted therapies and for interpreting functional genomics data.
hepatocyte growth factor receptor activity At A Glance
| GO ID | GO:0005008 |
|---|---|
| GO term | hepatocyte growth factor receptor activity |
| Ontology | molecular_function |
| Synonym | hepatocyte growth factor-activated receptor activity; HGF-activated receptor activity; HGF receptor activity |
| Major function | Binds hepatocyte growth factor and transmits signals across the plasma membrane to initiate cellular responses |
| Receptor protein | MET (c-Met) receptor tyrosine kinase |
| Ligand | Hepatocyte growth factor (HGF) |
| Downstream pathway | Phosphatidylinositol 3-kinase and other signaling cascades |
| Related disease | Cancer, liver regeneration, neuroinflammation |
What Is GO:0005008?
In simple terms, GO:0005008 describes the ability of a receptor on the cell surface to bind hepatocyte growth factor and send a signal into the cell. According to QuickGO, this molecular function is defined as combining with hepatocyte growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity. The receptor responsible is the MET proto-oncogene, a tyrosine kinase that autophosphorylates upon ligand binding and recruits adaptor proteins to propagate downstream signaling.
Why Is hepatocyte growth factor receptor activity Important in Cell Biology?
GO:0005008 is important because HGF/MET signaling controls fundamental processes such as cell proliferation, survival, migration, and morphogenesis, and its dysregulation contributes to cancer, tissue injury, and neurological disorders. The receptor activity is a validated drug target, and understanding its mechanism supports the development of inhibitors and agonists for therapeutic use.
• Drives hepatocyte proliferation and liver regeneration after injury.
• Is a key oncogenic driver in many cancers, making it a target for inhibitor development.
• Mediates neuroinflammation in diabetes-associated hippocampal dysfunction.
• Has cardioprotective potential in ischemic heart disease.
• Regulates phosphatidylinositol 3-kinase signaling, affecting cell survival and metabolism.
• Is regulated by ubiquitination, providing a mechanism for receptor activation.
• Serves as a model for receptor tyrosine kinase signaling studies.
• Enables computational design of novel therapeutic inhibitors.
• Supports regenerative medicine strategies through controlled activation.
• Provides a paradigm for understanding ligand-receptor interactions across the kinome.
What Happens During hepatocyte growth factor receptor activity?
Ligand binding and receptor dimerization
In simple terms: HGF binds to the MET receptor on the cell surface, causing two receptor molecules to pair up.
Hepatocyte growth factor (HGF) is the ligand for the MET receptor. Upon binding, MET undergoes dimerization and conformational changes that activate its intrinsic tyrosine kinase activity. This step is the initial event in GO:0005008 and is required for all downstream signaling.
Receptor autophosphorylation and kinase activation
In simple terms: The paired receptors add phosphate groups to each other, turning on their enzymatic activity.
Following dimerization, MET autophosphorylates specific tyrosine residues in its intracellular domain, which stabilizes the active kinase conformation and creates docking sites for adaptor proteins. This autophosphorylation is a hallmark of receptor tyrosine kinase activation and is essential for transmitting the signal.
Downstream signaling cascades
In simple terms: The activated receptor triggers a chain of signals inside the cell that change its behavior.
Activated MET recruits and activates multiple downstream pathways, including phosphatidylinositol 3-kinase (PI3K). This leads to changes in cell proliferation, survival, and migration, which are the cellular outcomes of GO:0005008.
Regulation by ubiquitination
In simple terms: Ubiquitin molecules can attach to the receptor and either turn it on or mark it for degradation.
MET activity is regulated by ubiquitination. MET-activating ubiquitin multimers can stimulate the receptor, indicating that ubiquitin modification is not only degradative but can also promote signaling. This adds a layer of complexity to the regulation of GO:0005008.
Key Genes Involved in GO:0005008 hepatocyte growth factor receptor activity
The following genes and proteins are central to hepatocyte growth factor receptor activity and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MET | Receptor tyrosine kinase that binds HGF and transmits signals | Primary molecule for GO:0005008; target for cancer therapy |
| HGF | Ligand that activates MET | Stimulates liver regeneration and cardioprotection |
| PIK3CA | Catalytic subunit of PI3K, activated downstream of MET | Mediates PI3K signaling from MET |
| PIK3R1 | Regulatory subunit of PI3K | Modulates PI3K activation by MET |
| KLK8 | Kallikrein-related peptidase 8, involved in HGF/Met signaling | Mediates diabetes-associated neuroinflammation |
| GAB1 | Adaptor protein recruited to activated MET | Scaffolds downstream signaling |
| GRB2 | Adaptor protein that links MET to RAS-MAPK pathway | Propagates MET signals |
| SRC | Non-receptor tyrosine kinase activated by MET | Contributes to MET-driven oncogenesis |
| STAT3 | Transcription factor activated downstream of MET | Promotes proliferation and survival |
| AKT1 | Serine/threonine kinase activated by PI3K | Mediates survival signals from MET |
| MAPK1 | Extracellular signal-regulated kinase 2 | Transmits proliferative signals from MET |
| CBL | E3 ubiquitin ligase that ubiquitinates MET | Regulates MET degradation and signaling |
| UBB | Ubiquitin B, forms multimers that can activate MET | Provides activating ubiquitin chains |
| CDH1 | E-cadherin, involved in MET-dependent cell adhesion | Modulates MET signaling in epithelial cells |
| VEGFA | Vascular endothelial growth factor A, induced by HGF | Links MET to angiogenesis |
| MMP2 | Matrix metalloproteinase 2, induced by HGF | Promotes invasion downstream of MET |
| TGFB1 | Transforming growth factor beta 1, interacts with HGF signaling | Modulates MET-driven fibrosis |
How Is hepatocyte growth factor receptor activity Regulated?
Hepatocyte growth factor receptor activity is regulated at multiple levels. Ligand availability controls activation, and receptor ubiquitination by E3 ligases such as CBL modulates receptor stability and signaling. Additionally, downstream phosphatidylinositol 3-kinase signaling provides feedback regulation. In pathological states, such as diabetes-associated neuroinflammation, the KLK8/HGF/Met pathway is dysregulated, indicating that extracellular proteases can influence receptor activity.
hepatocyte growth factor receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MET | Cancer, tumorigenesis | MET knockout or point-mutation cancer cell lines |
| HGF | Liver regeneration | HGF overexpression in hepatocytes |
| KLK8 | Diabetes-associated neuroinflammation | KLK8 knockout mice |
| MET | Cardioprotection in ischemic heart | Cardiac-specific MET knockout mice |
| PIK3CA | PI3K-mediated survival signaling | PIK3CA knock-in mutations |
Cancer
Dysregulated HGF/MET signaling is a driver of tumorigenesis, invasion, and metastasis. Phytochemicals such as neogitogenin and samogenin have been identified as potential HGF receptor-targeted cancer treatments, highlighting the therapeutic relevance of GO:0005008. Computational studies have also focused on identifying novel inhibitors of HGF receptor-ligand interactions.
Liver regeneration and injury
HGF receptor activity is critical for hepatocyte proliferation and liver regeneration. A bacterial HGF receptor agonist stimulated hepatocyte proliferation and accelerated liver regeneration in a partial hepatectomy rat model, demonstrating the regenerative potential of targeting GO:0005008.
Neuroinflammation
The KLK8/HGF/Met signaling pathway mediates diabetes-associated hippocampal neuroinflammation in male mice, linking GO:0005008 to neurological complications of diabetes.
Cardiovascular disease
Hepatocyte growth factor has been proposed as a cardioprotective protein in the ischemic heart, suggesting that HGF receptor activity may protect against myocardial injury.
From hepatocyte growth factor receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MET kinase activity drive proliferation? | MET knockout cell lines |
| Does a specific MET mutation alter ligand binding? | Point-mutation knock-in of MET |
| Can a tagged MET be used for imaging? | Tagged knock-in of MET (e.g., GFP) |
| Does MET overexpression transform cells? | MET overexpression stable cell lines |
| Is HGF required for liver regeneration? | HGF knockout mice |
| Does KLK8 regulate HGF/Met in neuroinflammation? | KLK8 knockout mice |
How to Study the hepatocyte growth factor receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality and pathway dependencies | Identify modulators of HGF/MET signaling |
| Phosphoproteomics | Phosphorylation of MET and downstream targets | Map signaling networks |
| Computational docking | Ligand-receptor binding affinity | Virtual screening for inhibitors |
| Immunoprecipitation | Protein-protein interactions of MET | Identify adaptors and effectors |
| Western blot | MET expression and phosphorylation | Validate activation status |
| qPCR | mRNA levels of MET and target genes | Assess transcriptional responses |
| Animal models | Tissue regeneration and inflammation | Preclinical efficacy studies |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes that modulate HGF receptor activity and downstream signaling, revealing synthetic lethal interactions in cancer cells.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics measures MET autophosphorylation and downstream phosphorylation events, providing a global view of signaling changes.
Computational modeling
Molecular dynamics and docking simulations can model HGF-MET interactions and predict novel inhibitors, as demonstrated in computational investigations.
Animal models
Partial hepatectomy rat models and knockout mice are used to study liver regeneration and neuroinflammation driven by HGF/MET signaling.
How CRISPR Can Be Used to Study GO:0005008 hepatocyte growth factor receptor activity
Knockout
CRISPR knockout of MET or HGF eliminates receptor activity, allowing researchers to test whether GO:0005008 is required for specific cellular responses such as proliferation or migration.
Point Mutation
Point mutations can be introduced into the MET kinase domain to mimic activating mutations found in cancer, enabling studies of how specific residues contribute to receptor activity.
Knock-in
Knock-in of tagged MET (e.g., GFP or HA) allows real-time imaging and biochemical isolation of the receptor, facilitating studies of its trafficking and interactions.
Overexpression
Overexpression of MET or HGF in cell lines can drive constitutive activation of GO:0005008, modeling oncogenic transformation and testing targeted inhibitors.
How EDITGENE Supports hepatocyte growth factor receptor activity Research
Researchers studying hepatocyte growth factor receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, and CRISPR-based models provide a direct way to test this.
Contact EDITGENE today to design your custom CRISPR model for hepatocyte growth factor receptor activity research.
Frequently Asked Questions About hepatocyte growth factor receptor activity
What is hepatocyte growth factor receptor activity?
It is a molecular function (GO:0005008) where the MET receptor binds HGF and transmits signals across the plasma membrane to change cell activity.
What genes are involved in hepatocyte growth factor receptor activity?
Key genes include MET (the receptor), HGF (the ligand), and downstream effectors such as PIK3CA, GAB1, and GRB2.
What is the role of MET in cancer?
MET activation drives proliferation, survival, and metastasis, making it a therapeutic target in many cancers.
How is hepatocyte growth factor receptor activity regulated?
It is regulated by ligand binding, receptor ubiquitination, and feedback from downstream pathways such as PI3K.
What diseases are associated with HGF receptor activity?
Cancer, liver injury, neuroinflammation, and cardiovascular disease have been linked to HGF/MET signaling.
Can CRISPR be used to study hepatocyte growth factor receptor activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect MET signaling.
What is the HGF/MET signaling pathway?
It is a signaling cascade initiated by HGF binding to MET, leading to receptor autophosphorylation and activation of PI3K and other pathways.
How does ubiquitination affect MET?
Ubiquitin multimers can activate MET, adding a non-degradative regulatory layer to receptor activity.
What model systems are used to study liver regeneration via HGF?
Partial hepatectomy rat models and HGF knockout mice are commonly used.
What is the clinical relevance of HGF receptor inhibitors?
Inhibitors targeting HGF/MET are being developed for cancer therapy, with computational and phytochemical studies identifying novel candidates.
Conclusion
Hepatocyte growth factor receptor activity (GO:0005008) is a critical molecular function mediated by the MET receptor tyrosine kinase. Its role in development, tissue regeneration, and disease makes it a prime target for therapeutic intervention and functional genomics research. Advances in CRISPR modeling and computational approaches continue to deepen our understanding of this pathway and its regulation.
References
- 1. Kawakami N et al.. 2023. MET-Activating Ubiquitin Multimers.. Angew Chem Int Ed Engl 62(36):e202307157 PMID: 37450419
- 2. Azmal M et al.. 2025. Computational investigation of hepatocyte growth factor receptor-ligand interactions for the identification of novel therapeutic inhibitors.. Comput Biol Med 198(Pt B):111250 PMID: 41138359
- 3. Galimi F et al.. 1993. The hepatocyte growth factor and its receptor.. Stem Cells 11 Suppl 2:22-30 PMID: 8401259
- 4. Kalinin EV et al.. 2021. Bacterial hepatocyte growth factor receptor agonist stimulates hepatocyte proliferation and accelerates liver regeneration in a partial hepatectomy rat model.. Drug Dev Res 82(1):123-132 PMID: 32830369
- 5. Elasbali AM et al.. 2024. Phytochemicals Neogitogenin and Samogenin Hold Potentials for Hepatocyte Growth Factor Receptor-Targeted Cancer Treatment.. OMICS 28(11):573-583 PMID: 39388097
- 6. Schaper W et al.. 1997. Is hepatocyte growth factor a protein with cardioprotective activity in the ischemic heart?. Circulation 95(11):2471-2 PMID: 9184574
- 7. Xu DH et al.. 2025. KLK8/HGF/Met signaling pathway mediates diabetes-associated hippocampal neuroinflammation in male mice.. Theranostics 15(13):6290-6312 PMID: 40521191
- 8. Cantley LG et al.. 1995. Signal transduction by the hepatocyte growth factor receptor, c-met. Activation of the phosphatidylinositol 3-kinase.. J Am Soc Nephrol 5(11):1872-81 PMID: 7620084
